These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 1458462)
21. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916 [TBL] [Abstract][Full Text] [Related]
22. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753 [TBL] [Abstract][Full Text] [Related]
23. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438 [TBL] [Abstract][Full Text] [Related]
24. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810 [TBL] [Abstract][Full Text] [Related]
25. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987 [TBL] [Abstract][Full Text] [Related]
26. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954 [TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246 [TBL] [Abstract][Full Text] [Related]
28. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072 [TBL] [Abstract][Full Text] [Related]
30. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128 [TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Miller AA; Al Omari A; Murry DJ; Case D Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403 [TBL] [Abstract][Full Text] [Related]
32. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734 [TBL] [Abstract][Full Text] [Related]
34. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625 [TBL] [Abstract][Full Text] [Related]
35. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806 [TBL] [Abstract][Full Text] [Related]
36. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703 [TBL] [Abstract][Full Text] [Related]
37. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364 [TBL] [Abstract][Full Text] [Related]
38. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125 [TBL] [Abstract][Full Text] [Related]
39. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Theriault RL; Walters RS; Holmes FA; Esparza-Guerra L; Kowal C; Hortobagyi GN Cancer Chemother Pharmacol; 1996; 38(3):289-91. PubMed ID: 8646805 [TBL] [Abstract][Full Text] [Related]
40. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]